|
||



* Division of Cell Biology, Max-Planck Institute for Developmental Biology, 72076 Tübingen, Germany; and
Department of
Genetics and Development, College of Physicians and Surgeons, Columbia University, New York 10032
| |
Abstract |
|---|
|
|
|---|
Axin was identified as a regulator of embryonic axis induction in vertebrates that inhibits the Wnt
signal transduction pathway. Epistasis experiments in
frog embryos indicated that Axin functioned downstream of glycogen synthase kinase 3
(GSK3
) and
upstream of
-catenin, and subsequent studies showed
that Axin is part of a complex including these two proteins and adenomatous polyposis coli (APC). Here, we
examine the role of different Axin domains in the effects on axis formation and
-catenin levels. We find that the regulators of G-protein signaling domain (major APC-binding site) and GSK3
-binding site are required, whereas the COOH-terminal sequences, including a protein phosphatase 2A binding site and the DIX
domain, are not essential. Some forms of Axin lacking the
-catenin binding site can still interact indirectly
with
-catenin and regulate
-catenin levels and axis
formation. Thus in normal embryonic cells, interaction
with APC and GSK3
is critical for the ability of Axin
to regulate signaling via
-catenin. Myc-tagged Axin is
localized in a characteristic pattern of intracellular spots as well as at the plasma membrane. NH2-terminal
sequences were required for targeting to either of these
sites, whereas COOH-terminal sequences increased localization at the spots. Coexpression of hemagglutinin-tagged Dishevelled (Dsh) revealed strong colocalization with Axin, suggesting that Dsh can interact with
the Axin/APC/GSK3/
-catenin complex, and may thus
modulate its activity.
-catenin;
glycogen synthase kinase 3
(GSK3
);
adenomatous polyposis coli (APC);
Dishevelled (Dsh);
dorsal axis formation
| |
Introduction |
|---|
|
|
|---|
AXIN is the product of the murine genetic locus originally called Fused, in which mutations cause a
variety of developmental defects (Gluecksohn-Schoenheimer, 1949
; Theiler and Gluecksohn-Waelsch, 1956
; Jacobs-Cohen et al., 1984
). The Axin gene was
cloned with the aid of an insertional mutation and found
to potentially encode a protein of up to 992 amino acids
(aa)1 (Perry et al., 1995
; Zeng et al., 1997
). Axin contains
two conserved domains, a regulators of G-protein signaling domain (RGS; Dohlman and Thorner, 1997
) near its
NH2 terminus and a COOH-terminal DIX domain (also
found in Dishevelled [Dsh]; Cadigan and Nusse, 1997
) that
suggested a role in signal transduction. More specific insight into the function of Axin came from studies of its effects on vertebrate embryogenesis. The occurrence of axial duplications in loss-of-function Axin mutants in the
mouse suggested that the gene might play a negative regulatory role in an early step in axis formation. This hypothesis was tested and confirmed by the ability of overexpressed Axin to block dorsal axis formation in Xenopus
embryos. Further studies showed that the effect of Axin is
due to its specific ability to inhibit signal transduction through components of the Wnt pathway and suggested
that Axin functioned downstream of glycogen synthase kinase 3
(GSK3
) and upstream of
-catenin (Zeng et al.,
1997
).
-Catenin is thought to serve as a key mediator of Wnt
signal transduction that is regulated through the following
mechanism (for review see Gumbiner, 1995
; Peifer, 1995
;
Miller and Moon, 1996
; Cadigan and Nusse, 1997
). In the
absence of a Wnt signal,
-catenin is confined to the
plasma membrane, where it stably is associated with cadherin adhesion molecules. Cytosolic
-catenin levels are
very low because free
-catenin is a target for GSK3
-dependent phosphorylation and is degraded rapidly via
the ubiquitin pathway. In the presence of a Wnt signal,
GSK3
phosphorylation of
-catenin is inhibited, free
-catenin is stabilized, accumulates in the cytoplasm, and
is imported into the nucleus.
-Catenin can interact with
HMG-box transcription factors of the TCF/Lef-1 family,
leading to activation of specific target genes.
Despite the apparent simplicity of this signaling cascade,
the mechanisms involved in the regulation of
-catenin are
still rather obscure. For instance, it is still not known
whether upstream components (Wnt, Frizzled, Dsh) affect
GSK3
activity or the accessibility of
-catenin to GSK3
.
The tumor suppressor gene product adenomatous polyposis coli (APC), which also binds directly to
-catenin, appears to be required to maintain low levels of
-catenin in mammalian cell lines (Munemitsu et al., 1995
). However,
experiments in embryonic systems are inconsistent with
APC being only a negative regulator of
-catenin and suggest that it might, on the contrary, be an activator of the
pathway (Rocheleau et al., 1997
; Vleminckx et al., 1997
).
Finally, there is still no definitive evidence that regulation
of the
-catenin level is the only important parameter in
-catenin signaling, or whether phosphorylation could affect directly its signaling activity. The apparent involvement
of Axin in Wnt signal transduction, at a level close to GSK3
and
-catenin, indicated that Axin might be at the heart of
the process of
-catenin phosphorylation/degradation.
To investigate the mechanism by which Axin participates in the regulation of Wnt signal transduction, we undertook a study of the interaction of Axin with various
components of the Wnt pathway. We also carried out a
functional dissection of the role of different regions of
Axin in its ability to ventralize frog embryos (an in vivo assay for inhibition of
-catenin signaling) or to influence
the levels of
-catenin in the frog embryo. During the
course of this work, several publications have described
the direct interaction of Axin with APC, GSK3
, and
-catenin (Hart et al., 1998
; Ikeda et al., 1998
; Itoh et al.,
1998
; Kishida et al., 1998
; Sakanaka et al., 1998
). These reports suggested that the primary function of Axin was to
bind GSK3
and
-catenin simultaneously, thus promoting the phosphorylation of
-catenin and its subsequent degradation. Similar results have been reported for an
Axin homologue called Axil or Conductin (Behrens et al.,
1998
; Yamamoto et al., 1998
). Both Axin and Axil/Conductin were found to bind to APC through their RGS domains (Behrens et al., 1998
; Hart et al., 1998
) and to
GSK3
and
-catenin through two distinct central domains (Behrens et al., 1998
; Ikeda et al., 1998
), thus mediating the formation of a multiprotein complex. However,
the RGS (APC-binding) domain was not required for
Axin to stimulate the phosphorylation of
-catenin in vitro
or its turnover in SW480 colon cancer cells (Behrens et al.,
1998
; Hart et al., 1998
; Ikeda et al., 1998
), raising questions
about the role of APC in this complex. In addition to these
proteins, Axin has been found to have a binding site for
the serine/threonine protein phosphatase 2A (PP2A),
which might modulate phosphorylation of proteins in the
complex, and another region that mediates multimerization with other Axin molecules. The latter region includes
the DIX domain, which is highly conserved between Axin
and Dsh, suggesting that Axin and Dsh might also interact
through this domain (Hsu et al., 1999
).
In the studies reported here, we have examined the regions of Axin required for its role in the regulation of axis
formation and
-catenin levels in the frog embryo. We
have found that in this system both the RGS domain and
GSK3
binding sites, but not necessarily the
-catenin
site, are essential for activity. We have shown that epitope-tagged Axin expressed in frog embryos is localized to the
plasma membrane and to a characteristic type of intracellular spots and have delimited the sequences in Axin that
mediate this pattern of localization. Finally, we have found that epitope-tagged forms of Axin and Dsh show strongly
overlapping patterns of localization when coexpressed,
suggesting that Dsh can also form part of the Axin complex.
| |
Materials and Methods |
|---|
|
|
|---|
Plasmid Construction
To express Myc-tagged forms of Axin, the coding region of mouse Axin
(form 1) sequence was inserted downstream of the SP6 promoter in the
vector pCS2-MT (Rupp et al., 1994
). DNA inserts amplified by PCR with
Pfu DNA polymerase (Stratagene) were used for the construction of plasmids containing small fragments, such as Ax455-552, Ax497-672, etc. Full-length (FL) Xenopus APC cDNA (Vleminckx et al., 1997
) was inserted
downstream of the CMV/SP6 promoter in the pCS2 vector, with a 5'
5× VSV-G (vesicular stomatitis virus glycoprotein) tag (YTDIEMNRLGK). Human Myc epitope-tagged APC constructs used for direct binding assays were described previously (Vleminckx et al., 1997
). pET32 vector (Novagen, Inc.) was used to produce the His·S tagged Axin fusion
proteins. The reading frame of all constructs was confirmed by sequencing
and detection of expected sized bands in Western blot or Coomassie brilliant blue R250 stained SDS-polyacrylamide gels. Plasmids for transfection and in vitro transcription/translation were isolated using the midi-prep kit (QIAGEN Inc.). Other constructs used included: Myc-tagged Xenopus
-catenin (Fagotto et al., 1996
), hemagglutinin (HA)-tagged Xenopus
-catenin (Funayama et al., 1995
), HA-tagged Xenopus Dsh (gift of Dr. U. Rothbächer, University of Marseille, France), HA-tagged
dominant negative human GSK3
(gift of Dr. X. He, Harvard Medical
School, Boston, MA).
Antibodies
Antibodies were purchased from the indicated sources: anti-
-catenin
mouse mAb, clone 14, and anti-GSK3
mAb, clone 7, Transduction Laboratories; anti-VSV-G mAb P5D4, Boehringer Mannheim; anti-Myc 9E10.2 mAb, Calbiochem-Novabiochem; anti-HA-tag rabbit polyclonal antibodies (pAb), Santa Cruz Biotechnology; and anti-
-galactosidase rabbit pAb, Cappel Laboratories and Organon Teknika Corp. Anti-Myc rabbit pAb was raised against the c-Myc-epitope tag (EQKLISEEDL) and affinity-purified. Anti-HA mAb 12CA5 was a gift from Dr. P. McCrea (M.D. Anderson Cancer Center, Houston, TX).
Tissue Culture and Transient Transfection
293 cells, obtained from the American Type Culture Collection, were cultured in DME/F12 medium (Mediatech) supplemented with 10% FBS
(HyClone Laboratories Inc.) in humidified 6% CO2. Cells were transfected using a calcium phosphate mammalian cell transfection kit (5 Prime
3 Prime, Inc.). The next day cells were collected and lysed and analyzed
for transient expression of transfected DNAs.
Immunoprecipitation (IP) and Western Blot
For IP and Western blot analysis, 293 cells were washed with PBS, pH 7.2, and lysed in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM NaF, 50 mM
KH2PO4, 10 mM sodium molybdate, 20 mM Tris-HCl, pH 7.4, 5 µg/ml
aprotinin, 5 µg/ml leupeptin, 0.6 mM DTT, 2 mM sodium orthovanadate,
0.2 mM PMSF, 1% Triton X-100). After 20 min at 4°C with constant rotation, the lysate was centrifuged at 14,000 g for 15 min and the supernatant
was saved. Protein concentration was measured by the Lowry method
(Lowry et al., 1951
). For coimmunoprecipitation (coIP) of Axin/APC/
-catenin/GSK3
complex, 150-300 µg (total protein) of cell lysate was
incubated with 1-2 µg of an appropriate antibody in lysis buffer for 2 h at 4°C with constant rotation. 30 µl of protein A/G plus-agarose (Santa
Cruz Biotechnology) was added and the incubation continued for an additional 1.5 h. Immunoprecipitates were pelleted and washed three times
with lysis buffer. Immunoprecipitates were analyzed by SDS-PAGE (5%
acrylamide for APC detection, 10% for detection of other proteins) and
Western blot, using HRP-conjugated donkey anti-rabbit and sheep anti-
mouse secondary antibodies (Amersham Life Science) and the chemiluminescence system (RENAISSANCETM; NEN Life Science Products).
Approximately 10-20 µg of protein was used to detect expression of the
various constructs.
Direct Binding Assay
Myc-APC constructs were produced with TNT coupled wheat germ extract system (Promega). These [35S]Met-labeled proteins were incubated with 2 µg of bacterially expressed S-tagged Axin fusion proteins in 500 µl of buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 5 mM DTT, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.1 mM PMSF, 0.5% NP-40 at 37°C for 10 min and at 4°C for 10 min. The protein complexes were precipitated with 30 µl S-protein agarose (Novagen), washed three times with the same incubation buffer, and analyzed by SDS-PAGE (7.5% gel) and autoradiography.
Mobility Shift Assay
Lysates from cells transiently expressing VSV-G-tagged APC (VSV-
APC) and Axin constructs were used for IP with anti-VSV-G P5D4 mAb.
Immunoprecipitates were incubated with 1,000 U of
-protein phosphatase (New England Biolabs Inc.) in 50 µl reaction buffer (50 mM Tris-HCl, pH 7.8, 5 mM DTT, 2 mM MnCl2, and 100 µg/ml BSA) at 30°C for 30 min.
-Protein phosphatase-treated samples were separated by SDS-PAGE (5% gels) and VSV-APC was detected by immunoblot using the
P5D4 mAb.
Embryo Injection and Scoring
mRNA was synthesized using SP6 polymerase (Promega) and dissolved in
diethyl pyrocarbonate-treated water. For ventralization assays, 15 nl
mRNA was injected in the subequatorial region of the two dorsal blastomeres of a four cell stage embryo. For axis duplication assays, 15 nl
mRNA was injected in one ventral blastomere. Ventralization was scored
at tailbud/tadpole stages according to the dorsoanterior index (Kao and
Elinson, 1988
). Axis duplication was scored at neurula/tailbud stage, in
four categories (Fagotto et al., 1997
): (1) complete secondary axis (including cement gland), (2) partial axis (no cement gland), (3) vestigial axis
(small remnants, blebs), and (4) normal. Only complete and partial axes were considered as bonafide secondary axes.
Expression Levels in Embryos
Expression levels of Myc-tagged Axin constructs were determined from NP-40 extracts of late blastula-early gastrula embryos (stage 9-10 1/2) by SDS-PAGE and immunoblot, using the anti-Myc-tag 9E10.2 mAb. NP-40 buffer had the following: 1% NP-40, 100 mM NaCl, 10 mM Hepes, pH 7.4, 1 mM EDTA, with a cocktail of protease inhibitors (1 mM PMSF, 1 µg/ml pepstatin A, 2 µg/ml leupeptin, 4 µg/ml aprotinin, 10 µg/ml antipain, 50 µg/ml benzamidine, 10 µg/ml soybean trypsin inhibitor, 100 µg/ml iodoacetamide).
Cell Fractionation
Early cleaving embryos were coinjected with 1 ng Myc-tagged Axin (Myc-
Axin) and 3 ng
-galactosidase mRNA. At stage 9-10, 10 embryos were
homogenized in 500 µl 250 mM sucrose, 110 mM potassium acetate, 10 mM Hepes, pH 7.4, 2 mM magnesium acetate, 2 mM DTT, 1 mM EDTA
supplemented with protease inhibitors. The homogenate was centrifuged
for 5 min at 1,500 g, and the low speed pellet was extracted in NP-40
buffer. The low speed supernatant was fractionated further by centrifugation for 30 min at 100,000 g in a tabletop ultracentrifuge (TL-100; Beckman Instruments Inc.) into a high speed pellet and supernatant. The fractions were analyzed for Myc-Axin and
-galactosidase by SDS-PAGE
and immunoblot.
Con A Precipitation
FL Axin or various mutant constructs mRNA were injected into 4-8-cell stage embryos. At stage 9-10, pools of six embryos were extracted in 500 µl NP-40 buffer and each extract was incubated with 50 µl of Con A-agarose beads (75% slurry; Sigma Chemical Co.) for 1-2 h at 4°C. The beads were spun down, the supernatant was collected (unbound fraction), the beads washed three times with 1 ml NP-40 buffer, and extracted by boiling in SDS-PAGE sample buffer (bound fraction). Levels of Myc-Axin constructs in bound and unbound fractions were analyzed by SDS-PAGE and immunoblot using the anti-Myc 9E10 mAb.
-Catenin Stability
HA-tagged
-catenin mRNA (75 pg) was coinjected with
-galactosidase
mRNA (control) or various Axin mutant mRNAs. Amounts of mRNA injected were the following:
-galactosidase, 1 ng; FL Axin (Ax12-956), 1 ng;
Ax12-531, 0.5 ng; Ax194-530, 0.5 ng; Ax194-672, 0.25 ng; Ax
251-351, 1 ng;
Ax331-956, 0.5 ng; and Ax531-956, 0.5 ng. Total amounts of injected
mRNA were adjusted to 1.075 ng by addition of
-galactosidase mRNA.
In some experiments (see Fig. 5 C), higher levels of
-catenin were tested
using 0.75-1.5 ng mRNA. Embryos were extracted in NP-40 buffer at
stage 9-10 and either directly analyzed by SDS-PAGE and immunoblot,
or cleared from cadherin-bound
-catenin as follows: six embryos were
extracted in 200 µl NP-40 buffer. 50 µl of Con A-agarose beads (75%
slurry) were added, and the samples were incubated with constant mixing for 1-2 h. The beads were spun down and discarded and the supernatant was analyzed for
-catenin levels using an anti-HA-tag rabbit antibody (Santa Cruz Biotech.), as well as for Axin mutant levels using the
9E10.2 mAb.
|
Immunofluorescence (IF)
Stage 9-11 embryos were fixed in 4% paraformaldehyde, 100 mM Hepes,
pH 7.4, 100 mM NaCl for 1 h at room temperature, then in Dent's fixative
(20% DMSO, 80% methanol) overnight at -20°C. They were rinsed in 100 mM Tris-HCl, 100 mM NaCl, and embedded in 15%, then 25% fish gelatin, and 10-µm cryosections were prepared as described (Fagotto and
Gumbiner, 1994
; Fagotto, 1999
). Sections were labeled with 9E10.2 mAb
and anti-mouse Oregon green488 or Alexa488 secondary antibodies (Molecular Probes Inc.), the yolk counterstained with Eriochrome back, and
nuclei with 4',6-diamidino-2-phenylindole (DAPI) as described (Fagotto,
1999
). For double staining, sections from embryos coinjected with Myc-
Axin and HA-tagged Dsh (HA-Dsh) mRNAs (1 ng each) were stained
simultaneously with anti-Myc rabbit pAb and anti-HA mAb 12CA5,
followed by Alexa488 goat anti-rabbit and Cy3 donkey anti-mouse
(Dianova) secondary antibodies.
For localization of Myc-Axin in cultured cells, HeLa cells cultured in DMEM were transfected with pCS2-Myc-Axin using LipofectAmine (GIBCO BRL). 36-48 h after transfection, cells were fixed in 4% paraformaldehyde/PBS, permeabilized with 0.05% Triton X-100, and labeled with anti-Myc 9E10.2 mAb and Cy3 goat anti-mouse (Dianova) secondary antibodies. Nuclei were counterstained with DAPI. Samples were observed with an Axioplan epifluorescence microscope (Zeiss) using standard fluorescein and Cy3 filters, and digital images were collected using a camera (768x576 3CCD color video; Sony).
Electron Microscopy and Immunogold Labeling
Preembedding labeling was performed as described (Kurth, 1997
; Fagotto,
1999
). In brief, embryos expressing FL Myc-Axin or Myc-Ax
531-810
were fixed at stage 10 with 4% paraformaldehyde, 0.02% glutaraldehyde,
and 100 mM Hepes-NaOH. Labeling was performed by incubating 100-µm
vibrotome sections with the 9E10.2 mAb and a Nanogold-coupled anti-
mouse secondary antibody, followed by silver enhancement. The reaction
produced electron dense aggregates with a diameter of ~20-60 nm (see
Fig. 8, C-E). The sections were embedded in Spurr resin and ultrathin sections were prepared.
|
Postembedding labeling was performed on small blebs obtained from
the wounds of injected embryos. These blebs contained a large number of
Axin-expressing cells, and their ultrastructure was better preserved than
in whole embryos (Kurth, 1997
). Paraformaldehyde/glutaraldehyde-fixed samples were processed for Lowycryl embedding, ultrathin sectioning, and immunogold labeling (9E10.2 mAb and 15 nm gold-coupled protein G) according to standard procedures.
| |
Results |
|---|
|
|
|---|
Binding of Full-length and Mutant Forms of Axin to
APC, GSK3
, and
-Catenin
When epitope-tagged full-length Axin (amino acids 12-
956) was expressed in 293 cells, endogenous GSK3
and
-catenin, as well as VSV-epitope tagged APC (VSV-
APC), could be coimmunoprecipitated (coIP) with Axin.
A variety of mutant forms of Axin were used next for coIP
and direct binding assays to further delimit the regions of
Axin required for these interactions (Figs. 1 and 2 and
data not shown) and to compare binding abilities with activity in functional assays (see below). The results are summarized in Fig. 3, which includes a schematic diagram of
Axin, indicating the locations of the major binding sites for
these proteins as well as PP2A binding and Axin self-binding (Hsu et al., 1999
).
|
|
|
The region of rAxin corresponding to aa 561-630 of
mAxin has been shown to contain a
-catenin binding site
(Ikeda et al., 1998
) and our results confirmed that all Axin
mutants containing this region could coIP with endogenous
-catenin. However, several mutants that lacked this
region but included the RGS domain (APC binding site)
were also able to coIP with
-catenin (Ax12-531, Ax194-531, and Ax
531-810) (Fig. 1 A and data not shown). This may be due to indirect interaction with
-catenin via APC,
because deletion of the RGS domain from this mutant
Axin (Ax12-531
251-351), which eliminated APC binding
(see below), also eliminated coIP with
-catenin (Fig. 1
A). The 85-aa region of rAxin corresponding to mAxin
477-561 was reported to bind to GSK3
(Ikeda et al., 1998
). We found that Ax497-600, Ax403-552, and Ax455-552 all showed strong coIP with GSK3
(Fig. 1 B), indicating that the binding site is located in the 55-aa segment between aa 497 and 552. Mutants that terminate at aa 531 either coIP very weakly (Ax12-531 and Ax194-531) or fail
to coIP with GSK3
(Ax12-531
251-351), suggesting that
truncation at this site partially disrupts the GSK3
binding site (Figs. 1 B and 3).
The RGS domain of Axin has been identified as a site
for direct interaction with the 20-aa repeat region of APC
(Hart et al., 1998
; Kishida et al., 1998
). We confirmed that
only Axin fragments including the RGS domain could
bind to the 20-aa repeat region of APC (APC2 or APC25)
(Fig. 2, A-C). However, we also found that a second region of Axin, between aa 96-253, could bind directly to the
NH2-terminal region of APC (APC21), which contains the Armadillo repeats and 15 aa repeats (Fig. 2 C). coIPs of
the Axin mutants with VSV-APC generally were dependent on the RGS domain: all mutants containing this domain were able to coIP with VSV-APC, whereas all but
one of those lacking it failed to coIP with VSV-APC (Figs.
2 D and 3). However, Ax331-956 also was able to coIP
with APC, probably via
-catenin (Fig. 2 D). The second
APC binding region (aa 96-253) was not sufficient for
coIP with VSV-APC (Fig. 2 D, Ax
251-351). Whether
Ax12-355 or Ax12-167 could coIP with VSV-APC could
not be determined because expression of these mutant Axins resulted in a strong reduction in the level of VSV-
APC (Fig. 2 E and data not shown).
Axin Overexpression Induces Phosphorylation of APC In Vivo
When FL Axin and VSV-APC were cotransfected into
293 cells, the electrophoretic mobility of VSV-APC was
reduced compared with control cells cotransfected with
VSV-APC plus pCS2 vector. Ax12-810 and Ax12-531
caused a similar mobility shift, whereas Ax
231-351, Ax12-355, and Ax497-672, which lack either the GSK3
or
APC binding site, did not (Fig. 2 E). It has been shown
that phosphorylation of APC by GSK3
(Rubinfeld et al.,
1996
) can be stimulated by Axin in vitro (Hart et al., 1998
).
To test whether this Axin-induced mobility shift was due
to phosphorylation, the immunoprecipitated proteins were
treated with
-protein phosphatase before immunoblot analysis with anti-VSV. This treatment eliminated the mobility shift, indicating that it was due to phosphorylation
(Fig. 2 F). This suggests that binding of APC and GSK3
to Axin promotes the phosphorylation of APC in vivo,
presumably by GSK3
(Rubinfeld et al., 1996
).
Axin Sequences Necessary for Ventralization of Xenopus Embryos
We previously have shown that the ability of Axin to inhibit dorsal axis formation, when expressed in early Xenopus embryos, is due to its inhibitory effect on the Wnt signaling pathway (Zeng et al., 1997
). Therefore, we used this
assay to delimit the sequences in Axin required for its negative effects on signaling through the Wnt pathway. 22 mutant forms of Axin were expressed by mRNA injection on
the dorsal side of 4-cell stage embryos that were cultured
to the tadpole stage and examined for the extent of dorsal axis formation (fraction of embryos ventralized and dorso-anterior index). The amount of injected mRNAs was systematically titrated to obtain comparable levels of expression for the various mutants. The results are summarized
in Fig. 3, the data are listed in Table I and examples are
shown in Fig. 4.
|
|
|
As we previously reported (Zeng et al., 1997
), an internal deletion of the RGS domain (Ax
251-351) eliminated the ability to ventralize and instead caused dorsalization. Deletion of the GSK3
and
-catenin binding sites
(Ax
352-631) also abolished ventralizing activity. A small
fragment containing the GSK3
and
-catenin binding
sites (Ax497-672) was insufficient to ventralize the embryo, although similar Axin fragments were able to promote phosphorylation of
-catenin in vitro (Ikeda et al.,
1998
). A fragment containing only the RGS domain
(Ax194-353) was also ineffective.
Successive truncation from the NH2 terminus of Axin
confirmed the importance of the RGS domain for ventralization. Whereas removal of the first 193 aa had no significant effect, further truncation to aa 331 eliminated ventralizing activity and resulted in dorsalizing activity, similar to
the internal RGS deletion (Fig. 4, D and F). Truncation at
aa 531, removing both the RGS domain and GSK3
binding region, eliminated all activity (Fig. 4 C) as did truncation to aa 810 (Ax810-956).
Mutant Axins with NH2-termini at aa 194 were subjected to COOH-terminal truncation to examine the importance of the DIX, PP2A binding,
-catenin binding,
and GSK3
binding domains. Removal of the DIX domain (Ax194-810) had little if any effect, whereas removal
of the DIX and PP2A binding domains (Ax194-672)
caused an increase in ventralizing activity (Fig. 4 B). This
observation is consistent with the hypothesis that the binding of PP2A to the Axin complex may negatively regulate
the phosphorylation of
-catenin by GSK3
(Hsu et al.,
1999
). Further truncation to aa 531, removing the
-catenin binding site, abolished ventralizing activity, and instead resulted in some dorsalizing activity (i.e., shorter
axis, larger head, and circular or double cement gland; Fig.
4 E). When injected at high concentrations, the other Axin mutants lacking the NH2-terminal and the COOH-terminal regions (Ax194-672 and Ax194-810) also showed dorsalizing activity, as discussed below.
When the NH2 terminus of Axin was left intact, truncation of the COOH terminus to remove the DIX domain,
or both the DIX and PP2A domains, caused only a slight
reduction, if any, in the ability to ventralize. Surprisingly,
there was no further reduction in activity when the region
including the
-catenin binding site was truncated (Ax12-531) or removed by an internal deletion (Ax
531-810). Unlike the mutants with NH2-termini truncated at aa 194, no dominant negative effect (dorsalization) was seen when
high concentrations were injected (Table II). Further truncation, removing the GSK3
site, eliminated all activity
(Ax12-355). Internal deletion of only the RGS domain, in
the context of COOH-terminal truncations (mutant Ax12-810
251-351, Ax12-672
251-351, and Ax12-531
251-351), also eliminated ventralizing activity and instead cause
weak dorsalizing activity.
Dorsalization
In contrast to the ability of Axin and other inhibitors of
Wnt signaling (e.g., GSK3
) to ventralize when injected
dorsally, factors that stimulate this pathway (e.g., certain
Wnts, Dsh, dnGSK3
, or
-catenin) have dorsalizing activity; when injected dorsally, they can hyperdorsalize (i.e.,
they induce formation of a larger head, large or multiple
cement glands, shorter axis, and double anterior axis).
However, their activity is best seen in ventral injections,
where they can induce a secondary axis (Miller and Moon,
1996
; Fagotto et al., 1997
; Fagotto, 1999
). We previously
showed that a mutant Axin lacking the RGS domain (Ax
251-351) behaved as such a dorsalizing factor. This
activity could be competed by coexpression of FL Axin,
supporting the conclusion that it was due to a dominant
negative effect (Zeng et al., 1997
). To identify the domains
of Axin required for this activity, several additional mutant forms of Axin were also injected into the ventral side
of the embryo to assay their ability to induce axis duplication.
Sequences upstream from the RGS domain were not required, as an NH2-terminal truncation at aa 331 (Ax331-956) induced axis duplication as efficiently as the RGS deletion (Figs. 3 and 4 F, Table II). However, the GSK3
binding site was required as truncation at aa 531 abolished
the effect (Ax531-956). The COOH-terminal sequences
were also important: in the presence of the RGS deletion, COOH-terminal truncation at aa 810, 672, or 530 strongly
reduced the dorsalizing activity so that axis duplication
was observed only when high concentrations of RNA were
injected. When the amount of injected RNA was titrated
down to yield expression levels at which Ax
251-351
showed optimal activity, only Ax331-956 was active (Table II).
Effects of Axin and Axin Mutants on
-Catenin levels
Modulation of the Wnt pathway has a striking effect on
-catenin levels; in the absence of a Wnt signal, constitutively active GSK3
phosphorylates
-catenin and causes
its rapid turnover, whereas Wnt signaling induces stabilization of
-catenin. Therefore, we tested the effect of
Axin on
-catenin levels in Xenopus embryos by coexpressing HA-tagged
-catenin with FL or mutant forms of Axin, or with
-galactosidase as a control. Low amounts of
HA-tagged
-catenin mRNA were used to mimic the behavior of endogenous
-catenin. At the late blastula stage,
when endogenous
-catenin signaling peaks (Lemaire et al.,
1995
; Schneider et al., 1996
), the levels of HA-tagged
-catenin in embryo extracts were analyzed. The membrane (cadherin-bound) pool of
-catenin is known to be
very stable (Kofron et al., 1997
) and changes in
-catenin
levels by the Wnt signaling pathway affect mostly the unbound, soluble pool (Riggleman et al., 1990
; Peifer et al.,
1994
; Pai et al., 1997
). Removing the cadherin-bound pool
of
-catenin by Con A precipitation made it possible to
obtain samples enriched in soluble
-catenin, allowing the
effect of Axin on
-catenin levels to be analyzed more accurately. As shown in Fig. 5 B, FL Axin caused a dramatic
decrease in exogenous
-catenin. Several mutant Axin
constructs were coexpressed similarly; mutants with ventralizing activity (Ax12-531 and Ax194-672) also proved to
be effective in reducing
-catenin levels. A mutant lacking
ventralizing activity (Ax531-956) had no effect on
-catenin levels. On the other hand, mutants with strong dominant negative activity (Ax
251-351 and Ax331-956), induced a clear increase in
-catenin levels. Unexpectedly,
mutant Ax194-531, which failed to ventralize over a wide
range of concentrations, but instead showed some dorsalizing activity, caused a strong decrease in
-catenin levels.
The activity of the dominant negative mutant Ax
251-351 was also tested on the ventral side, where the
-catenin degradation machinery is maximally active. Under
these conditions, stabilization of
-catenin by Ax
251-
351 could be observed even in total extracts (Fig. 5 C).
NH2 terminally deleted
-catenin (hemagglutinin epitope- tagged
-NH2 terminus
-catenin; Funayama et al., 1995
),
which lacks the GSK3
-dependent phosphorylation site
(Munemitsu et al., 1996
; Yost et al., 1996
), was found to be
insensitive to Axin overexpression (Fig. 5 D), suggesting
that Axin-induced destabilization of
-catenin requires
phosphorylation by GSK3
.
Intracellular Distribution of Axin
As the subcellular localization of endogenous Axin is so far unknown, we examined the distribution of the ectopically expressed Myc-tagged Axin in Xenopus embryos. As shown in Fig. 6, FL Myc-Axin exhibited a striking and unusual pattern. The signal was mostly concentrated in very bright spots, which were found singly or in clusters of variable size, mainly, but not exclusively, at the cell periphery (Fig. 6, A and A', arrows). The rest of the cytoplasm was devoid completely of the signal. In addition, some plasma membrane staining was also observed. However, the membrane staining was quite variable: absent in many cells, weak in others (Fig. 6, A and A'', arrowhead), and very strong in a few rare cells (not shown). The punctate pattern and the absence of diffuse cytoplasmic staining were observed at all mRNA concentrations used from 0.15 ng, the limit of detection by IF, to 2 ng. A similar pattern was observed in Axin-transfected cultured HeLa (Fig. 6, B and B') and A6 cells (not shown).
|
Myc-Axin localization in Xenopus embryos was further
studied at the EM level by two different techniques: on-section staining of Lowycryl sections (Fig. 7, A-C) and
preembedding labeling using Nanogold and silver enhancement (Fig. 7, D-F). Notwithstanding differences in
ultrastructure preservation and labeling sensitivity (see
legends), both methods gave similar results. Consistent
with IF data, Myc-Axin was found to be concentrated
highly in discrete areas of the cell. These areas were characterized by clusters of vesicles (asterisks) surrounded by
gold-decorated electron dense material (arrows). Labeled
clusters varied largely in size and density, apparently as a
function of expression levels. Part of a loose cluster is
shown in Fig. 7 C. Small groups of gold particles associated
with a few vesicles and electron dense material could be
resolved, probably corresponding to the individual spots detected by IF (Figs. 6 A' and 7 A, arrows). On the other
hand, Fig. 7, D and E, shows very large dense Myc-positive
areas, where vesicles were tightly packed and consequently the dense cytoplasm appeared less prominent. Fig.
7 B shows a cluster of intermediate size and vesicle density. Plasma membrane localization of FL Axin could not
be detected unambiguously by EM, probably because it was generally too weak (Fig. 6 A, IF). However, strong
plasma membrane staining could be observed for the mutant Axin Ax
531-810 that is consistent with IF results
(Fig. 3).
|
Consistent with the IF data, Axin was found to be largely particulate/sedimentable in differential centrifugation experiments (Fig. 8 B). On the other hand, it was completely solubilized in the presence of a mild nonionic detergent, NP-40 (Fig. 8 C). Thus, the sedimentation properties of Axin are not due to interaction with detergent-insoluble cytoskeletal elements. In the presence of NP-40, Axin could be partially precipitated using Con A beads (Fig. 8 C), indicating that a pool of Axin is associated with a membrane glycoprotein. We believe that this Axin- membrane association involves the plasma membrane pool of Axin, but not that in the intracellular spots, because binding to Con A of all Axin deletion mutants tested (Fig. 8 D) strictly correlated with plasma membrane localization (as detected by IF, see below).
Colocalization of Dsh with Axin
The punctate distribution of Axin strongly was reminiscent of the localization pattern of ectopically expressed
Dsh (Yang-Snyder et al., 1996
; Axelrod et al., 1998
) (the
distribution of endogenous Dsh in Xenopus is not known).
Thus, we compared the localization of coexpressed Myc-tagged Axin and HA-Dsh by double IF. We observed a
very good colocalization of these two proteins (Fig. 6, C
and C'): HA-Dsh was detected at all sites positive for
Myc-Axin (arrowheads), although some other spots were
positive for Dsh but negative for Axin (arrows). The Myc-
Axin pattern in these embryos was indistinguishable from
the pattern observed in the absence of exogenous Dsh,
suggesting that Dsh does not influence Axin localization.
In contrast, Myc-Axin overexpression clearly affected
HA-Dsh distribution: when HA-Dsh was expressed alone,
it localized exclusively in single cytoplasmic spots, or small
clusters of spots, distributed throughout the cell (Fig. 6 D).
No membrane staining was observed. However, when coexpressed HA-Dsh and Myc-Axin colocalized in a pattern typical for overexpressed Axin (enrichment of spots
at the cell periphery, presence of large clusters, and
plasma membrane staining). These results suggest that
Dsh may bind, directly or indirectly, to the Axin complex.
Sequences Required for Axin Localization
To examine the sequences in Axin that target it to its specific locations, and the functional significance of this localization, we examined the intracellular distribution of the
same mutant forms used above. Internal deletion of the
RGS domain had little or no effect on localization; the mutant protein localizing primarily in the spots and less at the
plasma membrane (Fig. 3 and Fig. 9, B and C). Deletion of
the GSK3
and
-catenin binding sites (Ax
352-631) also
had no effect on localization to the spots, but eliminated
the membrane staining (Fig. 9, H and I). Deletion of the
COOH-terminal 146-aa resulted in localization mainly at the membrane, with little or no labeling of the spots, e.g.,
Ax12-810 (not shown) Ax12-672 (Fig. 9 F), Ax12-531 (Fig.
9 G), and Ax12-355 (Fig. 9 J).
|
Forms of Axin lacking the NH2-terminal half displayed
a mostly diffuse cytoplasmic localization, e.g., Ax497-672
(Fig. 9 D). When the APC and GSK3
-binding domains
were left intact, there seemed to be some enrichment at
the cell periphery (Fig. 9 E, Ax194-956), although it was
difficult to assess the extent of membrane enrichment, because of the high cytoplasmic signal.
Thus, the NH2 terminus of Axin appears to be required
for the characteristic pattern of localization, both in the cytoplasmic spots and at the membrane. The presence of
the normal COOH terminus tends to cause localization to
the spots, although it is not absolutely required for this.
The COOH terminus, which includes a dimerization domain, might bind to endogenous Axin or to other cellular
components. The APC and GSK3
binding sites appear to
have a weaker effect on localization at the membrane. The
membrane localization of mutants containing the NH2 terminus correlates very well with Con A binding (Fig. 8 C).
For instance, Ax12-531 binds very efficiently to Con A,
whereas Ax531-956 does not bind at all. However, localization to the spots appears to depend on a different mechanism, only a small fraction of FL Axin and an even
smaller fraction of Ax
351-630 (found mostly in spots)
bind to Con A (Fig. 8 C and data not shown).
| |
Discussion |
|---|
|
|
|---|
Axin has been shown to negatively regulate signaling
through components of the Wnt pathway. Coinjection experiments in Xenopus embryos previously suggested that
it acts downstream of GSK3
and upstream of
-catenin.
Subsequent studies have shown that Axin is part of a complex including these two proteins as well as APC and that
it promotes the phosphorylation of
-catenin by GSK3
and its subsequent degradation (Hart et al., 1998
; Ikeda et
al., 1998
; Itoh et al., 1998
; Kishida et al., 1998
; Sakanaka et
al., 1998
). The aims of the experiments reported here were to understand the relationship between Axin's ability to
bind to these and other proteins and its capacity to function in the regulation of this pathway. To this end, we have
examined a series of Axin mutants for their ability to (1)
bind to APC, GSK3
, and
-catenin; (2) ventralize or dorsalize Xenopus embryos, an established assay for effects
on
-catenin signaling; and (3) alter the stability of
-catenin expressed from coinjected mRNA. In addition, we
have examined the intracellular localization of FL Axin
and a series of Axin mutants.
Interaction of Axin with Other Components of the Wnt Signaling Pathway
Through direct binding in vitro and coIP from mammalian
cell extracts, we have confirmed that Axin forms a complex with APC, GSK3
, and
-catenin, and we have further delimited some of the binding sites for these proteins.
Based on coIP, the region of mAxin required for interaction with GSK3
lies between aa 497 and 531. The
COOH-terminal boundary of the minimal binding region appears to lie between aa 526 and 531. Whereas Itoh et al.
(1998)
did not detect coIP of GSK3
with Axin 12-526, we
detected weak interaction of GSK3
with some Axin mutants terminating at aa 531. We confirmed that the RGS
domain (aa 220-340) includes a major binding site for
APC and interacts with the 20-aa repeat region of APC.
Furthermore, we identified a second region of Axin, between aa 96-253, that can bind directly to the NH2-